Combating Thermostability with the World’s First Approved Lyophilised mRNA-Based Vaccine

Time: 1:45 pm
day: Day One Track B PM


  • Developing the first self-amplifying mRNA vaccine to gain European approval
  • Benchmarking the convenience of 2-8 degrees Celsius storage and supply, pharmacoeconomics and reachability
  • Advancing needle free delivery
  • Showcasing self-sufficiency of raw materials, ease of manufacturing and stockpiling